Serum M30 levels are associated with survival in advanced gastric carcinoma patients
- 31 July 2010
- journal article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 10 (7), 719-722
- https://doi.org/10.1016/j.intimp.2010.03.013
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activityMolecular Cancer Therapeutics, 2008
- The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survivalLung Cancer, 2007
- Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to ChemotherapyClinical Cancer Research, 2007
- Cell death modalities: classification and pathophysiological implicationsCell Death & Differentiation, 2007
- Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot StudyCancer Investigation, 2006
- Detection of epithelial cell death in the body by cytokeratin 18 measurementBiomedicine & Pharmacotherapy, 2005
- Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18Cancer Research, 2004
- Measurement of an apoptotic product in the sera of breast cancer patientsEuropean Journal of Cancer, 2003
- Release of cytokeratin‐18 and ‐19 fragments (TPS and CYFRA 21‐1) into the extracellular space during apoptosisJournal of Cellular Biochemistry, 2002
- Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosisThe Journal of Pathology, 1999